BioCentury
ARTICLE | Clinical News

AmpliPhi reports data from expanded access program for bacteriophages

January 12, 2018 6:11 PM UTC

AmpliPhi Biosciences Corp. (NYSE-M:APHB) reported data from seven patients with serious, life-threatening infections who did not respond to antibiotics from an expanded access program showing that AB-SA01 or AB-PA01 (Biophage-PR, AmpliPhage-001) in combination with best available antibiotic therapy led to treatment success, defined as complete resolution or significant improvement of baseline signs and symptoms, in six patients. Four patients with Staphylococcus aureus infections received IV AB-SA01 and three patients with Pseudomonas aeruginosa infections received IV AB-PA01. The products were well tolerated with no treatment-related serious adverse events reported. The program plans to enroll up to an additional 20 patients this half...

BCIQ Company Profiles

AmpliPhi Biosciences Corp.